Tetrabenazine has 20 known drug interactions based on U.S. FDA drug labeling data. Of these, 6 are contraindicated combinations that should be avoided entirely. 13 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbidopa And Levodopa, Deutetrabenazine, Maois. Patients taking Tetrabenazine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Contraindicated
- 6
- Major
- 13
- Moderate
- 1
Contraindicated (6)
- Tetrabenazine + Carbidopa And Levodopa— Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic…
- Tetrabenazine + Deutetrabenazine— Contraindicated in patients currently taking tetrabenazine. Deutetrabenazine may be initiated the day following disconti…
- Tetrabenazine + Maois— Tetrabenazine is contraindicated in patients taking MAOIs. Should not be used within minimum of 14 days of discontinuing…
- Tetrabenazine + Monoamine Oxidase Inhibitors (Maois)— Tetrabenazine is contraindicated in patients taking MAOIs. Minimum 14 days must elapse after discontinuing MAOI before s…
- Tetrabenazine + Reserpine— Should not be used concomitantly. Must wait at least 20 days after stopping reserpine before starting tetrabenazine to a…
- Tetrabenazine + Valbenazine— Concurrent use is contraindicated.
Major (13)
- Tetrabenazine + Amiodarone— Class III antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation …
- Tetrabenazine + Chlorpromazine— Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly…
- Tetrabenazine + Fluoxetine— Strong CYP2D6 inhibitor that markedly increases exposure to tetrabenazine metabolites. Dose reduction necessary; maximum…
- Tetrabenazine + Haloperidol— Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly…
- Tetrabenazine + Moxifloxacin— Antibiotic known to cause QTc prolongation. Concomitant use should be avoided due to additive QTc prolongation risk.
- Tetrabenazine + Olanzapine— Antipsychotic that increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.
- Tetrabenazine + Paroxetine— Strong CYP2D6 inhibitor that markedly increases exposure to tetrabenazine metabolites. Dose reduction necessary; maximum…
- Tetrabenazine + Procainamide— Class IA antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation r…
- Tetrabenazine + Quinidine— Strong CYP2D6 inhibitor that markedly increases exposure to tetrabenazine metabolites. Dose reduction necessary; maximum…
- Tetrabenazine + Risperidone— Antipsychotic that increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.
- Tetrabenazine + Sotalol— Class III antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation …
- Tetrabenazine + Thioridazine— Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly…
- Tetrabenazine + Ziprasidone— Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly…
Moderate (1)
- Tetrabenazine + Alcohol— Concomitant use may have additive effects and worsen sedation and somnolence.